Men aged 18 to 39 lag behind other populations in awareness and treatment of high blood pressure, putting them at increased risk for MI and stroke, according to research published in Hypertension.

ABBOTT PARK, Ill., Aug. 28, 2017 — Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev™ HeartMate 3™ Left Ventricular Assist System (also known as an LVAD).

Warfarin and three direct oral anticoagulants are associated with different patterns of thrombus-formation inhibition under flow conditions, patterns which can be identified by means of visual analysis using a microchip flow chamber system, a new study finds.

For the first time, researchers have shown that lowering inflammation, regardless of cholesterol levels, can help prevent recurrent heart attacks.

Over the past quarter-century, the worldwide burden of rheumatic heart disease has declined although high rates of the illness persist in certain poor regions, including Oceania, South Asia and sub-Saharan Africa, a new study finds.

Orsiro drug-eluting stents (DES) outperformed the current standard device for percutaneous coronary intervention (PCI) in a randomized international trial, according to a presentation from the European Society of Cardiology Congress.

U.S. scientists in July edited the DNA of a human embryo. It’s a first, it’s just the beginning and could someday mean the end of children born with hypertrophic cardiomyopathy. Imagine wiping out sudden cardiac death in young athletes someday.  

A daily treatment regimen of rivaroxaban and aspirin was associated with a 24 percent decreased risk of major adverse cardiovascular events (MACE) compared to aspirin-only therapy in patients with stable atherosclerotic vascular disease, according to new research published in The New England Journal of Medicine.